Show simple item record

dc.creatorKer, Sheryl
dc.creatorHsu, Jennifer
dc.creatorBalani, Anisha
dc.creatorMukherjee, Sankha Subhra
dc.creatorRush, A. John
dc.creatorKhan, Mehreen
dc.creatorElchehabi, Sara
dc.creatorHuffhines, Seth
dc.creatorDeMoss, Dustin
dc.creatorRenteria, Miguel E.
dc.creatorSarkar, Joydeep
dc.date.accessioned2022-01-31T17:27:27Z
dc.date.available2022-01-31T17:27:27Z
dc.date.issued2021
dc.identifier.urihttps://doi.org/10.2147/NDT.S331442
dc.identifier.urihttps://repository.tcu.edu/handle/116099117/49948
dc.description.abstractPurpose: To describe attrition patterns of opioid use disorder (OUD) patients treated with buprenorphine (BUP) and to assess how clinical, sociodemographic, or BUP medication dosing features are associated with attrition. Patients and Methods: Electronic health records of adults (16+ year-olds) with OUD treated with BUP from 23 different substance use or mental health care programs across 11 US states were examined for one year following BUP initiation in inpatient (IP), intensive outpatient (IOP), or outpatient (OP) settings. Treatment attrition was declared at >37 days following the last recorded visit. Survival analyses and predictive modelling were used. Results: Retention was consistently 2-3 times higher following BUP initiation in OP (n = 2409) than in IP/IOP (n = 2749) settings after 2 (50% vs 25%), 6 (27% vs 9%) and 12 months (14% vs 4%). Retention was higher for females, whites (vs blacks), and those with less severe OUD, better global function, or not using non-psychotropic medications. Comorbid substance use, other psychiatric disorders, and the number of psychotropic medications were variously related to retention depending on the setting in which BUP was initiated. Predictive modelling revealed that a higher global assessment of functioning and a smaller OUD severity based on the Clinical Global Impression - Severity led to longer retentions, a higher initial BUP dose led to higher retention in a few cases, an OP setting of BUP initiation led to longer retentions, and a lower total number of psychotropic and non-psychotropic medications led to longer retentions. These were the most important parameters in the model, which identified 75.2% of patients who left BUP treatment within three months post-initiation, with a precision of 90.5%. Conclusion: Of all the OUD patients who began BUP, 50-75% left treatment within three months, and most could be accurately identified. This could facilitate patient-centered management to better retain OUD patients in BUP treatment.
dc.language.isoenen_US
dc.publisherDove Medical Press Ltd
dc.rights.urihttps://creativecommons.org/licenses/by-nc/3.0/
dc.sourceNeuropsychiatric Disease and Treatment
dc.subjectopioids
dc.subjectbuprenorphine
dc.subjectbuprenorphine dosing
dc.subjecttreatment engagement
dc.subjecttreatment retention
dc.subjecttreatment dropout
dc.subjectpredictors
dc.titleFactors That Affect Patient Attrition in Buprenorphine Treatment for Opioid Use Disorder: A Retrospective Real-World Study Using Electronic Health Records
dc.typeArticle
dc.rights.holder2021 Authors
dc.rights.licenseCC BY-NC 3.0
local.collegeBurnett School of Medicine
local.departmentBurnett School of Medicine
local.personsDeMoss (SOM)


Files in this item

Thumbnail
This item appears in the following Collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc/3.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc/3.0/